Ajanta Pharma Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Yogesh Agrawal
Chief executive officer
₹156.3m
Total compensation
| CEO salary percentage | 71.4% |
| CEO tenure | 16.4yrs |
| CEO ownership | 14.6% |
| Management average tenure | no data |
| Board average tenure | 13.3yrs |
Recent management updates
Recent updates
With EPS Growth And More, Ajanta Pharma (NSE:AJANTPHARM) Makes An Interesting Case
Jun 01
Ajanta Pharma Limited (NSE:AJANTPHARM) Analysts Are Pretty Bullish On The Stock After Recent Results
May 05Ajanta Pharma Limited's (NSE:AJANTPHARM) Intrinsic Value Is Potentially 23% Below Its Share Price
Apr 05We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease
Feb 23Ajanta Pharma Limited (NSE:AJANTPHARM) Investors Are Less Pessimistic Than Expected
Dec 23Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly
Aug 26These 4 Measures Indicate That Ajanta Pharma (NSE:AJANTPHARM) Is Using Debt Reasonably Well
Feb 07Here's Why Ajanta Pharma (NSE:AJANTPHARM) Has Caught The Eye Of Investors
Oct 24Estimating The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Aug 25Is Now The Time To Put Ajanta Pharma (NSE:AJANTPHARM) On Your Watchlist?
Jul 19A Look At The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Apr 28Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly
Mar 14I Built A List Of Growing Companies And Ajanta Pharma (NSE:AJANTPHARM) Made The Cut
Feb 06Estimating The Fair Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Dec 13Ajanta Pharma (NSE:AJANTPHARM) Will Pay A Dividend Of ₹9.50
Oct 31Here's Why We Think Ajanta Pharma (NSE:AJANTPHARM) Is Well Worth Watching
Sep 22Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 27% Discount?
Sep 08Does Ajanta Pharma (NSE:AJANTPHARM) Have A Healthy Balance Sheet?
Aug 26Here's Why Shareholders Will Not Be Complaining About Ajanta Pharma Limited's (NSE:AJANTPHARM) CEO Pay Packet
Jul 07Should You Be Adding Ajanta Pharma (NSE:AJANTPHARM) To Your Watchlist Today?
Jun 14Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 30% Discount?
May 15Ajanta Pharma Limited (NSE:AJANTPHARM) Vies For A Place In Your Dividend Portfolio: Here's Why
Apr 10Ajanta Pharma Limited's (NSE:AJANTPHARM) Has Had A Decent Run On The Stock market: Are Fundamentals In The Driver's Seat?
Mar 11Does Ajanta Pharma (NSE:AJANTPHARM) Deserve A Spot On Your Watchlist?
Feb 24The Ajanta Pharma (NSE:AJANTPHARM) Share Price Is Up 56% And Shareholders Are Holding On
Jan 30
What Can We Make Of Ajanta Pharma's (NSE:AJANTPHARM) CEO Compensation?
Jan 18Estimating The Fair Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Jan 06What Percentage Of Ajanta Pharma Limited (NSE:AJANTPHARM) Shares Do Insiders Own?
Dec 25You Have To Love Ajanta Pharma Limited's (NSE:AJANTPHARM) Dividend
Dec 13Is Ajanta Pharma Limited's (NSE:AJANTPHARM) Recent Stock Performance Influenced By Its Financials In Any Way?
Dec 01With EPS Growth And More, Ajanta Pharma (NSE:AJANTPHARM) Is Interesting
Nov 19CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | ₹8b |
| Dec 31 2023 | n/a | n/a | ₹7b |
| Sep 30 2023 | n/a | n/a | ₹7b |
| Jun 30 2023 | n/a | n/a | ₹6b |
| Mar 31 2023 | ₹156m | ₹112m | ₹6b |
| Dec 31 2022 | n/a | n/a | ₹6b |
| Sep 30 2022 | n/a | n/a | ₹7b |
| Jun 30 2022 | n/a | n/a | ₹7b |
| Mar 31 2022 | ₹163m | ₹94m | ₹7b |
| Dec 31 2021 | n/a | n/a | ₹7b |
| Sep 30 2021 | n/a | n/a | ₹7b |
| Jun 30 2021 | n/a | n/a | ₹7b |
| Mar 31 2021 | ₹128m | ₹75m | ₹7b |
| Dec 31 2020 | n/a | n/a | ₹6b |
| Sep 30 2020 | n/a | n/a | ₹6b |
| Jun 30 2020 | n/a | n/a | ₹5b |
| Mar 31 2020 | ₹107m | ₹66m | ₹5b |
| Dec 31 2019 | n/a | n/a | ₹4b |
| Sep 30 2019 | n/a | n/a | ₹4b |
| Jun 30 2019 | n/a | n/a | ₹4b |
| Mar 31 2019 | ₹99m | ₹61m | ₹4b |
| Dec 31 2018 | n/a | n/a | ₹4b |
| Sep 30 2018 | n/a | n/a | ₹5b |
| Jun 30 2018 | n/a | n/a | ₹5b |
| Mar 31 2018 | ₹44m | ₹13m | ₹5b |
Compensation vs Market: Yogesh's total compensation ($USD1.87M) is above average for companies of similar size in the Indian market ($USD533.82K).
Compensation vs Earnings: Yogesh's compensation has been consistent with company performance over the past year.
CEO
Yogesh Agrawal (51 yo)
16.4yrs
Tenure
₹156,300,000
Compensation
Mr. Yogesh Mannalal Agrawal, M.B.A, has been Managing Director at Ajanta Pharma Ltd. since December 14, 2007. Mr. Agrawal is handling global business of Ajanta Pharma Ltd.He has handled various aspects of...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD & Executive Director | 24.1yrs | ₹156.30m | 14.6% ₹ 42.5b | |
| Joint MD & Director | 11.1yrs | ₹156.30m | 14.6% ₹ 42.5b | |
| Executive Vice Chairman of the Board | 26.4yrs | ₹36.21m | no data | |
| Lead Independent Director | 15.6yrs | ₹1.19m | no data | |
| Director of Ajanta Pharma USA Inc. | no data | ₹25.50m | no data | |
| Chairman of the Board | 44.4yrs | ₹704.00k | no data | |
| Non-Executive Independent Director | 9.9yrs | ₹833.00k | no data | |
| Non-Executive Independent Director | 11.1yrs | ₹923.00k | no data | |
| Non-Executive Independent Director | 9.9yrs | ₹749.00k | no data | |
| Director of Ajanta Pharma Philippines Inc. | no data | no data | no data | |
| Director of Ajanta Pharma (Mauritius) Ltd. | no data | no data | no data | |
| Director of Ajanta Pharma (Mauritius) Ltd. | no data | no data | no data |
13.3yrs
Average Tenure
71.5yo
Average Age
Experienced Board: AJANTPHARM's board of directors are seasoned and experienced ( 13.3 years average tenure).